KMDA
KMDA clinical trials: KAMADA LTD
Every trial on ClinicalTrials.gov where KAMADA LTD is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 11
- As lead sponsor
- 5
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
KMDA on the catalyst calendar · KMDA registry changes
- Primary completion Feb 19, 2026ActualPhase 3NCT04204252Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"Kamada, Ltd. · Alpha 1-Antitrypsin DeficiencyTerminatedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 13, 2019ActualPhase 3NCT02912845Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to RabiesKamada, Ltd. · RabiesCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2019ActualPhase 2NCT02614872Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung TransplantationKamada, Ltd. · Transplantation, Lung RejectionCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2014ActualPhase 2/Phase 3NCT02040090Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy SubjectsKamada, Ltd. · RabiesCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 26, 2020ActualPhase 1/Phase 2NCT04550325Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19Kamada, Ltd. · Covid19CompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2016ActualPhase 2NCT02001688Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"Kamada, Ltd. · Alpha-1 Antitrypsin DeficiencyCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2014ActualPhase 2/Phase 3NCT01217671International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient...Kamada, Ltd. · EmphysemaCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2017ActualPhase 2NCT02005848Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 DiabetesKamada, Ltd. · New Onset Type-1 DiabetesCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2012ActualPhase 1/Phase 2NCT01304537Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes MellitusKamada, Ltd. · Type 1 Diabetes MellitusCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2008ActualPhase 2NCT00499837Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis PatientsKamada, Ltd. · Cystic FibrosisCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredPhase 2/Phase 3NCT00460096Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin DeficiencyKamada, Ltd. · Alpha 1-Antitrypsin DeficiencyCompletedKMDALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 4NCT07009548CytoGam for CMV Infection or Disease in Solid Organ Transplant RecipientsFernanda P Silveira, MD, MS · Cytomegalovirus (CMV) InfectionEnrolling by invitationKMDACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2027Sponsor estimatePhase 4NCT06958796Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)Camille N. Kotton, MD · CytomegalovirusRecruitingKMDACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 3, 2018ActualPhase 2/Phase 3NCT02956122A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHDBaxalta now part of Shire · Graft Versus Host DiseaseTerminatedTAKLeadKMDACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT03172455Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell...Impatients N.V. trading as myTomorrows · Acute-graft-versus-host DiseaseNo longer availableKMDACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2017ActualPhase 2NCT01661192Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 DiabetesRabin Medical Center · Type 1 DiabetesCompletedKMDACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner